$BNTX News
Last published 1w ago
- 1w agoBNTXBioNTech Announces Third Quarter 2026 Financial Results and Corporate UpdateGlobeNewswireDelivered the first global data for any PD-(L)1xVEGF bispecific immunomodulator candidate in combination with an investigational antibody-drug conjugate in lung cancer, with pumitamig plus elfetabart drozuntecanAdvanced
- 2w agoHYFTMRNAMRKBNTXA Personalized Cancer Therapy Delivered Positive Phase 3 Results; The Next Race Is Picking Better TargetsGlobeNewswireAUSTIN, Texas, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Biotech Insider News Commentary - An mRNA-based cancer therapy designed around each patient’s own tumor has delivered positive Phase 3 results. On October 22, Merck and
- 2w agoBNTXBioNTech and DualityBio Announce Topline Results of the DYNASTY-Breast02 Global Phase 3 Clinical Trial Evaluating Trastuzumab Pamirtecan in HR+/HER2-low Metastatic Breast CancerGlobeNewswireMAINZ, Germany and SHANGHAI, China, October 26, 2026 – BioNTech SE (NASDAQ:BNTX, "BioNTech")) and DualityBiologics (Suzhou) Co., Ltd. ("DualityBio", HKEX: 9606.HK) announced today that the
- 2w agoBNTXBMYBioNTech and Bristol Myers Squibb Report Encouraging Global Phase 2 Data for Pumitamig in Advanced NSCLC After Progression on Immunotherapy Plus ChemotherapyGlobeNewswirePumitamig plus docetaxel demonstrated encouraging responses in squamous and non-squamous non-small cell lung cancer across PD-L1 expression levels with a confirmed objective response rate of 36.7% following progression
- 2w agoBNTXBioNTech Advances Phase 3 Clinical Trial of Pumitamig in Combination with Gilead’s TROP2-Directed ADC Sacituzumab Govitecan in Triple-Negative Breast CancerGlobeNewswireBioNTech enters a clinical trial collaboration with Gilead Sciences with the aim of improving outcomes in patients with PD-L1 low or negative triple-negative breast cancerThe global Phase 3 ROSETTA Breast-01 trial will
- 3w agoBNTXBioNTech to Report Third Quarter 2026 Financial Results and Corporate Update on November 3, 2026GlobeNewswireMAINZ, Germany, October 20, 2026 (GLOBE NEWSWIRE) – BioNTech SE (NASDAQ:BNTX, "BioNTech" or "the Company")) will announce its financial results for the third quarter 2026 on Tuesday, November 3, 2026.
- 3w agoBNTXBioNTech to Showcase Oncology Late-Stage Pipeline Progress and Pumitamig Novel-Novel Combination Data at ESMO 2026GlobeNewswireLate-breaking oral presentation will feature first data from the global ROSETTA Lung-107 Phase 2 clinical trial evaluating pumitamig, a PD-L1×VEGF-A bispecific immunomodulator, plus docetaxel in patients with metastatic
- 4w agoBNTXBioNTech Provides Update on Phase 2/3 Clinical Trial for mRNA Cancer Immunotherapy Candidate BNT113 in Metastatic HPV16-positive Head and Neck CancerGlobeNewswireAHEAD-MERIT Phase 2/3 clinical trial did not meet its first dual primary endpoint of progression-free survival for the mRNA cancer immunotherapy candidate BNT113 plus pembrolizumab compared with pembrolizumab alone The
- 1mo agoNNVCGILDMRNAPFE+1A $57 Billion Antiviral Market Is Taking Shape As The World Prepares For The Next Viral ThreatGlobeNewswireNEW YORK, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Market News Updates News Commentary - The antiviral market is entering a period where the need for new treatments is becoming impossible to ignore. Viral outbreaks can
- 1mo agoBNTXBioNTech and OncoC4 Present Updated Data Showing Gotistobart Nearly Doubled Median Overall Survival versus Standard-of-Care Chemotherapy in Previously Treated Squamous Non-Small Cell Lung Cancer PatientsGlobeNewswireGotistobart continues to show potential as chemotherapy-free monotherapy to reignite anti-tumor immunity in previously treated patients with squamous non-small cell lung cancer, where median survival with current
- 2mo agoPFEBNTXPfizer and BioNTech Receive U.S. FDA Approval for XFG-adapted COVID-19 VaccineBusiness Wire2026-2027 COVID-19 vaccine formula targets the XFG variant, in line with FDA guidance to more closely match contemporary circulating variants Shipping will begin immediately to ensure rapid access to this season’s
- 2mo agoBNTXPFEPfizer and BioNTech Receive U.S. FDA Approval for XFG-adapted COVID-19 VaccineGlobeNewswire2026-2027 COVID-19 vaccine formula targets the XFG variant, in line with FDA guidance to more closely match contemporary circulating variantsShipping will begin immediately to ensure rapid access to this season’s
- 2mo agoSBFMBNTXAZNMRNA+1A Multibillion-Dollar mRNA Cancer Market Is Taking Shape Targeting Lung Cancer’s Biggest OpportunityGlobeNewswireNEW YORK, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Market News Updates News Commentary - If watching where cancer treatment is headed, mRNA cancer vaccines are hard to ignore—especially in lung cancer. The basic idea is
- 2mo agoBNTXBioNTech Highlights Late-Stage Lung Cancer Pipeline Momentum and First Global Data for Pumitamig/Elfetabart Drozuntecan Novel-Novel Combination at WCLC 2026GlobeNewswirePumitamig plus B7H3-targeting elfetabart drozuntecan delivers the first data in lung cancer for any PD-(L)1xVEGF bispecific immunomodulator combined with an antibody-drug conjugate, underscoring BioNTech’s leadership in
- 3mo agoBNTXBioNTech Announces Second Quarter 2026 Financial Results and Corporate UpdateGlobeNewswireGuido Oelkers, Ph.D., appointed to BioNTech Management Board as Chief Executive Officer, taking office by February 1, 2027, at the latestAdvanced diversified pipeline now with 14 ongoing pivotal clinical trials and more
- 3mo agoBNTXBioNTech Announces Appointment of Guido Oelkers to Management Board as Chief Executive OfficerGlobeNewswireMainz, Germany, August 3, 2026 (GLOBE NEWSWIRE) – BioNTech SE (NASDAQ:BNTX, "BioNTech" or "the Company")) announced today that its Supervisory Board has appointed Guido Oelkers, Ph.D., to the Management
- 3mo agoBNTXPFEEuropean Commission Authorizes Pfizer and BioNTech XFG-adapted COVID-19 Vaccine in the European UnionGlobeNewswireData indicate that the 2026-2027 COVID-19 vaccine formula, targeting the XFG variant, induces a strong immune response against contemporary circulating and emerging lineages More than five billion doses of the
- 3mo agoPFEBNTXEuropean Commission Authorizes Pfizer and BioNTech XFG-adapted COVID-19 Vaccine in the European UnionBusiness WireData indicate that the 2026-2027 COVID-19 vaccine formula, targeting the XFG variant, induces a strong immune response against contemporary circulating and emerging lineages More than five billion doses of the
- 3mo agoBNTXBioNTech to Report Second Quarter 2026 Financial Results and Corporate Update on August 4, 2026GlobeNewswireMAINZ, Germany, July 21, 2026 (GLOBE NEWSWIRE) – BioNTech SE (NASDAQ:BNTX, "BioNTech" or "the Company")) will announce its financial results for the second quarter 2026 on Tuesday, August 4, 2026.
- 4mo agoBNTXSMMTCGONNTHIThe New War on Cancer: Four Public Companies Helping Lead a Medical RevolutionGlobeNewswireDENVER, June 25, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) – Cancer treatment is undergoing one of the most significant transformations in modern medical history. For decades, physicians relied primarily on
- 5mo agoMBGSCAN-BSHLASML+8How corporate–scale-up partnering can boost Europe’s tech competitivenessMcKinsey - Technology, Media, and Telecommunications
- 5mo agoBNTXIBRXKZIANTHIThe Multi-Billion-Dollar Search for Better Glioblastoma TreatmentsGlobeNewswireDENVER, June 03, 2026 (GLOBE NEWSWIRE) -- (www.247marketnews.com) – Cancer treatment has advanced dramatically over the past two decades. Precision medicine, immunotherapy, antibody-drug conjugates, and targeted
- 5mo agoBMYBNTXCARBOPLATINGlobal Data for BioNTech and Bristol Myers Squibb's PD-L1xVEGF-A Bispecific Pumitamig Shows Encouraging Efficacy in Patients with Non-Small Cell Lung Cancer in ROSETTA Lung-02 TrialGlobeNewswireFirst investigational PD-(L)1xVEGF bispecific immunomodulator to present global data showing encouraging efficacy in combination with chemotherapy in first-line non-small cell lung cancer across PD-L1 expression levels
- 5mo agoBNTXBioNTech to Showcase Progress Across Late-Stage Oncology Pipeline at the 2026 ASCO Annual MeetingGlobeNewswirePumitamig data from the ongoing Phase 2/3 ROSETTA Lung-02 trial in first-line non-small cell lung cancer mark the third global data set to consistently show encouraging anti-tumor activity for pumitamig in combination
- 6mo agoBNTXBioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2026GlobeNewswireMAINZ, Germany, May 15, 2026 (GLOBE NEWSWIRE) -- BioNTech SE (NASDAQ:BNTX, "BioNTech" or "the Company")) held its Annual General Meeting ("AGM") today. A total of 92 per cent of the share capital was represented at the
- 6mo agoBNTXBioNTech Announces New ADS Repurchase ProgramGlobeNewswireMAINZ, Germany, May 7, 2026 (GLOBE NEWSWIRE) -- BioNTech SE (NASDAQ:BNTX, "BioNTech" or "the Company")) today announced that it has authorized a new share repurchase program (the "Program"), under which the Company may
- 6mo agoBNTXBioNTech Announces First Quarter 2026 Financial Results and Corporate UpdateGlobeNewswireFive additional pivotal trials for pumitamig initiated during 2026 in collaboration with Bristol Myers SquibbOncology pipeline strength and combination strategy highlighted through multiple clinical data updates,
- 6mo agoBNTXBioNTech to Report First Quarter 2026 Financial Results and Corporate Update on May 5, 2026GlobeNewswireMAINZ, Germany, April 21, 2026 (GLOBE NEWSWIRE) -- BioNTech SE (NASDAQ:BNTX, "BioNTech" or "the Company")) will announce its financial results for the first quarter 2026 on Tuesday, May 5, 2026. Additionally, the Company
- 7mo agoBNTXBioNTech and DualityBio's Antibody-Drug Conjugate Trastuzumab Pamirtecan Demonstrated Clinically Meaningful Efficacy in Patients with HER2-Expressing, Recurrent Endometrial CancerGlobeNewswireTrastuzumab pamirtecan, an investigational HER2-targeted antibody-drug conjugate, met the primary efficacy endpoint in a Phase 2 cohort of heavily pre-treated patients with HER2-expressing, recurrent endometrial cancer,
- 7mo agoBNTXBioNTech Clinical Data at ELCC 2026 Highlight Potential of Differentiated Late-Stage Portfolio in Lung CancerGlobeNewswirePresentations showcase progress in BioNTech's late-stage lung cancer programs, reinforcing the potential of the Company's differentiated portfolio spanning immunomodulators, antibody-drug conjugates, mRNA cancer
- 8mo agoBNTXBioNTech Announces Fourth Quarter and Full Year 2025 Financial Results and Corporate UpdateGlobeNewswireBioNTech on track for a catalyst-rich year with six late-stage data readouts expected across immunomodulators, antibody-drug conjugates and mRNA cancer immunotherapies Increased focus on PD-L11/VEGF-A bispecific
- 8mo agoBNTXBioNTech and Co-Founders Announce Plan to Pursue Next-Generation mRNA Innovations in Co-Founders-Led New Company as BioNTech Advances Toward Becoming a Multi-Product Company by 2030GlobeNewswireBioNTech continues to sharpen its strategic focus on the growing late-stage clinical pipeline spanning immunomodulator, ADC and mRNA candidatesBioNTech co-founders Ugur Sahin and Özlem Türeci will establish an
- 8mo agoONCYIBRXCRSPBNTX+1Immuno-Oncology Investments Accelerate as Pipeline Catalysts Multiply in 2026PR NewswireEquity Insider News Commentary, The immuno-oncology market is forecast to grow from $65.22 billion in 2025 to $170.19 billion by 2032, fueled by...
- 8mo agoBNTXBioNTech to Report Fourth Quarter and Full Year 2025 Financial Results and Corporate Update on March 10, 2026GlobeNewswireMAINZ, Germany, February 24, 2026 (GLOBE NEWSWIRE) -- BioNTech SE (NASDAQ:BNTX, "BioNTech" or "the Company")) will announce its financial results for the fourth quarter and full year 2025 on Tuesday, March 10, 2026.
- 9mo agoONCYBNTXMAIAACRV+1Late-Stage Breakthroughs: How 2026's Top Clinical Platforms Are Redefining Cancer TreatmentPR NewswireUSANewsGroup.com News Commentary – As the global oncology clinical trials market surges toward a projected $25.61 billion valuation by 2035[1], a...
- 9mo agoBNTXBioNTech Announces Appointment of Kylie Jimenez to Management Board as Chief People OfficerGlobeNewswireMainz, Germany, January 28, 2026 (GLOBE NEWSWIRE) – BioNTech SE (NASDAQ:BNTX, "BioNTech" or "the Company")) announced today that the Supervisory Board has appointed Kylie Jimenez to the Management Board as Chief People
- 10mo agoBNTXCMPXIBRXONCYThe $185B Cancer Surge: Why the FDA's Fast-Track Pivot is Scaling a New Immunotherapy EraGlobeNewswireVANCOUVER, British Columbia, Jan. 14, 2026 (GLOBE NEWSWIRE) -- USANewsGroup.com News Commentary – The global immuno-oncology market is set to explode from its current $35 billion level to a massive $185.69 billion by
- 10mo agoBNTXBioNTech Provides Strategic Business Update and Outlines 2026 Areas of Focus at 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewswire2026 poised to be a catalyst-rich year for BioNTech with continued late-stage pipeline progress with candidates across immunomodulators, antibody-drug conjugates and mRNA immunotherapiesExpected 2026 oncology milestones
- 10mo agoBMYBNTXCVACBioNTech Closes Acquisition of CureVac N.V. Including Subsequent Offering Period to Strengthen its Unique Position in the mRNA FieldGlobeNewswireBioNTech has completed its exchange offer to acquire CureVacAcquisition complements BioNTech's capabilities and proprietary technologies in mRNA design, delivery formulations, and mRNA manufacturingIn total,
- 11mo agoBMYBNTXBioNTech and Bristol Myers Squibb Present First Global Phase 2 Data for PD-L1xVEGF-A Bispecific Antibody Pumitamig Showing Encouraging Efficacy in Advanced Triple-Negative Breast CancerGlobeNewswireGlobal interim Phase 2 data in locally advanced/metastatic triple-negative breast cancer ("TNBC") show encouraging antitumor activity for investigational therapy pumitamig (BNT327/BMS986545) plus chemotherapy in first-
- 11mo agoBNTXBioNTech and OncoC4 Announce Clinically Meaningful Overall Survival Benefit for Selective Treg Modulator Gotistobart in Patients with Previously Treated Squamous Non-Small Cell Lung CancerGlobeNewswireSelective Treg modulator gotistobart (BNT316/ONC-392) showed a reduction in the risk of death by more than half compared to standard of care chemotherapy and a manageable safety profile in the first of two stages of the
- 11mo agoBNTXCVACBioNTech Achieves Minimum Condition in CureVac Exchange OfferGlobeNewswireThe minimum condition for the offer has been satisfied, with 184,071,410 shares of CureVac, representing approximately 81.74% of CureVac's issued and outstanding shares, tendered prior to the expiration of the initial
- 11mo agoBNTXCVACBioNTech Shares Progress on Exchange Offer for CureVac Shares and Highlights December 3, 2025, at 9:00 a.m. Eastern Time ExpirationGlobeNewswireOffer set to expire at 9:00 am Eastern Time on December 3, 2025, with CureVac shareholders advised to tender their shares by 6:00 pm Eastern Time on December 2, 2025, due to operational deadlines.Exchange ratio of
- 1y agoBNTXBioNTech Announces Third Quarter 2025 Financial Results and Corporate UpdateGlobeNewswireContinued clinical execution of oncology strategy with focus on two pan-tumor programs, including combination approaches to address the full continuum of cancer from early to late disease stagesDemonstrated encouraging
- 1y agoBNTXBioNTech to Host Innovation Series R&D Day on November 11, 2025GlobeNewswireMAINZ, Germany, October 28, 2025 (GLOBE NEWSWIRE) -- BioNTech SE (NASDAQ:BNTX, "BioNTech" or "the Company")), will host an edition of the Company's Innovation Series R&D Day at 09:00 a.m. Eastern Standard Time (3:00
- 1y agoBNTXBioNTech to Report Third Quarter 2025 Financial Results and Corporate Update on November 3, 2025GlobeNewswireMAINZ, Germany, October 27, 2025 (GLOBE NEWSWIRE) -- BioNTech SE (NASDAQ:BNTX, "BioNTech" or "the Company")) will announce its financial results for the third quarter 2025 on Monday, November 3, 2025. Additionally, the
- 1y agoBNTXCVACBioNTech Commences Public Exchange Offer for All Outstanding Shares of CureVac N.V.GlobeNewswireAcquisition aims to strengthen the research, development, manufacturing and commercialization of mRNA-based cancer immunotherapy candidates, marking BioNTech's next milestone in the execution of its oncology
- 1y agoBNTXBioNTech to Host Second AI Day as an Edition of Its Innovation Series on October 1, 2025GlobeNewswireMAINZ, Germany, September 23, 2025 (GLOBE NEWSWIRE) -- BioNTech SE (NASDAQ:BNTX, "BioNTech")), alongside its artificial intelligence ("AI") company InstaDeep Ltd. ("InstaDeep"), will host its second AI Day, an edition of
- 1y agoTEMCRSPBNTXBMYGlobal Cell Therapy Market Size Expected to Reach $44 Billion as Demand for Regenerative Medicine RisesPR NewswireCell therapy refers to a treatment that involves the use of living cells to treat diseases. The cell therapy market has been experiencing significant ...
- 1y agoBMYBNTXFirst Disclosure of Global Interim Phase 2 Data for BioNTech and Bristol Myers Squibb PD-L1xVEGF-A Bispecific Antibody Pumitamig (BNT327/BMS986545) in Patients with Extensive-Stage Small Cell Lung Cancer Shows Encouraging Antitumor ActivityGlobeNewswirePD-L1xVEGF-A bispecific antibody pumitamig (BNT327/BMS986545) plus chemotherapy continues to show encouraging antitumor activity in patients with extensive-stage small cell lung cancer ("ES-SCLC"), expanding evidence for